Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue

Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5. doi: 10.1073/pnas.92.15.7001.

Abstract

A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 +/- 0.09 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone. L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, luteinizing hormone, thyroxine, and prolactin after oral administration of 1 mg/kg. Only modest increases in cortisol were observed. Based on these properties, L-163,191 has been selected for clinical studies.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Aldosterone / blood
  • Amino Acid Sequence
  • Animals
  • Benzazepines / pharmacology
  • Cells, Cultured
  • Dogs
  • Drug Design
  • Drug Synergism
  • Growth Hormone / metabolism*
  • Indoles / administration & dosage*
  • Indoles / pharmacology
  • Injections, Intravenous
  • Luteinizing Hormone / blood
  • Male
  • Molecular Sequence Data
  • Oligopeptides
  • Pituitary Gland / drug effects*
  • Prolactin / blood
  • Rats
  • Spiro Compounds / administration & dosage*
  • Spiro Compounds / pharmacology
  • Structure-Activity Relationship
  • Tetrazoles / pharmacology
  • Thyroxine / blood

Substances

  • Benzazepines
  • Indoles
  • Oligopeptides
  • Spiro Compounds
  • Tetrazoles
  • L 692429
  • Aldosterone
  • growth hormone releasing hexapeptide
  • Prolactin
  • Luteinizing Hormone
  • Growth Hormone
  • Thyroxine
  • ibutamoren mesylate